Cover Image
Market Research Report

Global Pharmacovigilance Market - 2019-2026

Published by DataM Intelligence Product code 787198
Published Content info
Delivery time: 1-2 business days
Price
Back to Top
Global Pharmacovigilance Market - 2019-2026
Published: February 10, 2020 Content info:
Description

Pharmacovigilance Market Overview

Pharmacovigilance (PV) refers to the science and activities associated with detection, understanding, assessment, and prevention of adverse effects or any other drug-related problem. The focus of pharmacovigilance is on ADR (adverse drug reactions) and drug toxicity. The global pharmacovigilance market size was worth $ XX billion in 2018 and is estimated to reach $ XX billion by 2026, growing at a CAGR of 12.43 % during the forecast period (2019-2026).

Pharmacovigilance Market Dynamics

The global phenylketonuria (PKU) treatment market is growing due to factors such as rising incidence rates of adverse drug reactions, increasing drug consumption, and outsourcing of pharmacovigilance services.

The rising incidences of lifestyle diseases, such as hypertension, cardiac disorders, and diabetes caused by sedentary lifestyles, changing lifestyle patterns, lack of physical activities and poor diets, leads to high consumption of drugs. Increasing consumption of drugs leads to high demand for monitoring of drugs, thus boosting the growth of the pharmacovigilance market.

In addition, increasing adverse drug reactions (ADRs) is also driving the growth of the market during the forecast period. According to the National Centre for Biotechnology Information (NCBI), the number of fatalities due to ADRs has increased twice more than in 2017, which led to rise in hospitalizations. Also, in 2018, there was 10% increase in ADR rate in Brazil per medication introduced during hospitalization. Thus, rising number of ADRs needs continuous pharmacovigilance, hence driving the market growth.

The pharmaceutical companies are investing heavily in the R&D of new drugs to enhance the patients' health and quality of life. For instance, Astra, a pharmaceutical company has more than 100 permanent, experienced staff in pharmacovigilance within its R&D organization in Sweden and the United Kingdom, and a similar number in local operating companies worldwide. Hence, increasing advancement in developemnt of drugs is expected to drive the growth of the pharmacovigilance market during the forecast period.

However, lack of skilled healthcare professionals and high risk for data security that can be misused by the pharmacovigilance personnel are some of the factors hampering the growth of the market.

Pharmacovigilance Market Segment Analysis

On the basis of service provider, the pharmacovigilance market is segmented into outsourcing and in-house pharmacovigilance. Among these, the outsourcing pharmacovigilance accounted for the largest market share share in in 2018, owing to cost-effectivity and better monitoring of drug safety. Outsourcing eliminates the risk of business overhead costs as well as deployment of a pharmacovigilance resources. Hence, there is a positive shift in pharmacovigilance outsourcing due to more benefits such as handling of large data volume coupled with regulatory compliance which further boost the growth of the market. Increasing acceptance and adoption of outsourcing services by healthcare companies is expected to drive the growth of the pharmacovigilance market. Several small pharmaceutical companies outsource some of its drug safety work to a third-party while 85% of medium sized and 40% large size companies outsource pharmacovigilance.

By type of reporting, the market is segmented into intensified ADR reporting, spontaneous reporting, cohort event monitoring (CEM), targeted spontaneous reporting, and EHR mining. Among these, the spontaneous reporting segment is expected to hold highest market share over the forecast period, due to extensive usage in detection of new, serious, and rare ADRs and serves as an efficient and inexpensive method. Wide usage of surveillance reports generated through this method by pharmaceutical industries and regulatory authorities is also responsible for the significant market share of spontaneous reporting.

On the other hand, the cohort event monitoring (CEM) is estimated to grow at the fastest growth rate, owing to rising demand in detection of wide range of adverse clinical events. Conjugation of CEM with statistical tools and data mining systems such as longitudinal health records are responsible for the growing popularity of this segment. It serves as an active form of surveillance method which can also be used for new as well as older medicines, driving growth of this segment.

Pharmacovigilance Market Geographical Analysis

North America is dominating the global pharmacovigilance market in 2018, and is expected to hold the highest market share during the forecast period (2019-2026), owing to the shifting of high costs of in-house pharmacovigilance activities to CROs. According to Journal of American Medical Association (2017), 1 out of 3 drugs in the United States have the safety issues. Hence, there is a need for modifying the current protocols for quick communication between healthcare providers and the FDA needs to be strengthened.

Pharmacovigilance Market Competitive Landscape

The global pharmacovigilance market is moderately competitive and consists of several major players. Some of the major players in the market include: Cognizant, Accenture, Foresight Group International AG, IBM Corporation, Laboratory Corporation of America Holdings, ArisGlobal, Capgemini, ICON PLC, Wipro Ltd, BioClinica, among others.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the pharmacovigilance market globally. For instance,

In May 2019, Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the Post-marketing Adverse Drug Experience (PADE) inspection, indicating successful closure of the inspection.

In January 2019, Quanticate has launched QVigilance to provide dedicated pharmacovigilance (PV) and risk management services. QVigilance will be focused on supporting small and mid-size companies transitioning from clinical trials to post-marketing and establishing compliant PV systems.

In January 2019, Iqvia has developed a SaaS safety platform designed to reduce the cost and complexity of pharmacovigilance activities and help companies add value back into their business.

In June 2018, LabCorp, a leading global life sciences company, has acquired Sciformix Corporation, a scientific process outsourcing company focused on pharmacovigilance and regulatory solutions for biopharmaceutical and medical devices clients.

Why Purchase the Report?

  • Visualize the composition of the pharmacovigilance market segmentation by service provider, type of reporting, clinical trial phase, and end-user highlighting the key commercial assets and players.
  • Identify commercial opportunities in pharmacovigilance market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of pharmacovigilance market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global pharmacovigilance market report would provide an access to an approx. 62 market data table, 60 figures and 260 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
Table of Contents

Table of Contents

1. Global Pharmacovigilance Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Pharmacovigilance Market - Market Definition and Overview

3. Global Pharmacovigilance Market - Executive Summary

  • 3.1. Market Snippet by Service Provider
  • 3.2. Market Snippet by Type of Reporting
  • 3.3. Market Snippet by Clinical Trial Phase
  • 3.4. Market Snippet by End-User
  • 3.5. Market Snippet by Region

4. Global Pharmacovigilance Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising drug consumption and drug development rates
      • 4.1.1.2. Increasing trend of outsourcing pharmacovigilance services
    • 4.1.2. Restraints
      • 4.1.2.1. High risk associated with data security
      • 4.1.2.2. Lack of global regulatory harmonization and lack of data standardization for adverse event collection
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Pharmacovigilance Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Product Innovations
  • 5.5. Unmet Needs

6. Global Pharmacovigilance Market - By Service Provider

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider Segment
  • 6.3. Market Attractiveness Index, By Service Provider Segment
    • 6.3.1. Contract Outsourcing*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. In-house

7. Global Pharmacovigilance Market - By Type of Reporting

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting Segment
  • 7.3. Market Attractiveness Index, By Type of Reporting Segment
    • 7.3.1. Intensified ADR Reporting*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Spontaneous Reporting
    • 7.3.3. Cohort Event Monitoring
    • 7.3.4. Targeted Spontaneous Reporting
    • 7.3.5. EHR Mining

8. Global Pharmacovigilance Market - By Clinical Trial Phase

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase Segment
  • 8.3. Market Attractiveness Index, By Clinical Trial Phase Segment
    • 8.3.1. Preclinical*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Phase I
    • 8.3.3. Phase II
    • 8.3.4. Phase III
    • 8.3.5. Phase IV

9. Global Pharmacovigilance Market - By End-User

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
  • 9.3. Market Attractiveness Index, By End-User Segment
    • 9.3.1. Hospitals*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Pharmaceutical Companies
    • 9.3.3. Others

10. Global Pharmacovigilance Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Service Provider
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Reporting
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Clinical Trial Phase
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global Pharmacovigilance Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Pharmacovigilance Market- Company Profiles

  • 12.1. Cognizant*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Accenture
  • 12.3. Foresight Group International AG
  • 12.4. IBM Corporation
  • 12.5. Laboratory Corporation of America Holdings
  • 12.6. ArisGlobal
  • 12.7. Capgemini
  • 12.8. ICON PLC
  • 12.9. Wipro Ltd
  • 12.10. BioClinica

LIST NOT EXHAUSTIVE

13. Global Pharmacovigilance Market - Premium Insights

14. Global Pharmacovigilance Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us
Back to Top